BNF:

Not listed

Status:

Red

Decision Date:

November 2016

Comments

RED: NICE TA653 for treating EGFR T790M mutation-positive locally advanced or metastatic NSCLC. (Decision date - November 2020)

RED: NICE TA654 for untreated EGFR mutation-positive NSCLC. (Replaces TA621). (Decision date - November 2020)

RED: NICE TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (decision date March 25)

RED: NICE TA1060 - Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (Decision date June 2025)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again